KristiJoMcIntyreMD

Oncology • Dallas, TX

Physician

Join to view full profile

Dr. McIntyre is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. McIntyre's full profile

Already have an account?

Office
8196 Walnut Hill Ln
Ste 100
Dallas, TX 75231
Phone+1 214-739-4175

Fax+1 214-987-4161
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1988 - 1989
University of Mississippi Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
University of Mississippi Medical CenterResidency, Internal Medicine, 1982 - 1986
Tulane University School of MedicineClass of 1982

Certifications & Licensure

TX State Medical License 1991 - 2024
LA State Medical License 1982 - 2004
FL State Medical License 1990 - 2002
MN State Medical License 1989 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Start of enrollment: 2018 Oct 31
Completed
Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Recruiting
Phase 2, Phase 3
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
Active, not recruiting
Phase 3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Start of enrollment: 2021 Oct 04
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

60 citations
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Arash Jamshidi, Minetta C Liu, Eric A Klein, Oliver Venn, Earl Hubbell, John F Beausang, Samuel Gross, Collin Melton, Alexander P Fields, Qinwen Liu, Nan Zhang, Eric T...> ;Cancer Cell. 2022 Dec 12
66 citations
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...
C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark, J O'Shaughnessy, D Maag, M Untch, M Golshan, J Ponce Lorenzo, O Metzger, M Dunbar, W F Symmans, P Rastogi, J H Soh...> ;Annals of Oncology. 2022 Apr 1
15 citations
Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Joyce O'Shaughnessy, Kristi McIntyre, Sharon Wilks, Ling Ma, Margaret Block, David Andorsky, Michael A. Danso, Tracy Locke, Amy Scales, Yunfei Wang> ;JAMA Network Open. 2021 Apr 1
7 citations
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Peter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, Alexander S. Rosemurgy, Sharona Ross, Donald A. Richards, William E. Fisher, Patrick J. Flynn, Alicia Mattson, C...> ;Journal of Pancreatic Cancer. 2021 Mar 23
8 citations
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus‐Associated Stomatitis: A Randomized Phase II Study
Vicky E. Jones, Kristi McIntyre, Devchand Paul, Sharon Wilks, Sharon M. Ondreyco, Scot Sedlacek, Anton Melnyk, Sanjay P. Oommen, Yunfei Wang, Susan Peck, Joyce O'Shaug...> ;The Oncologist. 2019 Sep 1
3 citations
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Lee S. Schwartzberg, Kristi McIntyre, Sharon Wilks, Shannon Puhalla, Joyce O'Shaughnessy, Erhan Berrak, Yaohua He, Linda T. Vahdat> ;BMC Cancer. 2019 Jun 13
439 citations
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a ra...
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M. Sikov, Hope S. Rugo, Mark D. McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag, Daniell...> ;The Lancet. Oncology. 2018 Apr 1
12 citations
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
James R. Berenson, Robert F. Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger M. Lyons, Wael A. Harb, Hesham Mohamed, Ali Nourbakhsh, Robert M. Rifkin> ;American Journal of Hematology. 2017 May 1
71 citations
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: ...
Ian E. Smith, Denise A. Yardley, Howard A. Burris, Richard De Boer, Dino Amadori, Kristi McIntyre, Bent Ejlertsen, Michael Gnant, Walter Jonat, Kathleen I. Pritchard, ...> ;Journal of Clinical Oncology. 2017 Jan 23
13 citations
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Ca...
Svetislava J. Vukelja, Anthony D. Hoffman, Vicky E. Jones, Kristi McIntyre, Erhan Berrak, James Song, Joyce O'Shaughnessy> ;Clinical Breast Cancer. 2016 Feb 1
1 citations
Case Studies in the Management of Metastatic Breast Cancer with Eribulin
Sharon Wilks, Kristi McIntyre> ;Clinical Medicine Insights. Oncology. 2015 Oct 14
10 citations
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, sing...
Joyce O'Shaughnessy, Kristi McIntyre, Lee S. Schwartzberg, Sharon Wilks, Shannon Puhalla, Erhan Berrak, James Song, Linda T. Vahdat> ;Springerplus. 2015 Sep 21
49 citations
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Joyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen, Lea Krekow, Frankie A. Holmes, Svetislava J. Vuke...> ;Clinical Cancer Research. 2015 Jun 3
Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre, K.,O'Shaughnessy, J.,Schwartzberg, L.,Glück, S.,Berrak, E.,Song, J. X.,Cox, D.,Vahdat, L. T.> ;Breast Cancer Res. Treat.. 2014 Jun 20
48 citations
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
Kristi McIntyre, Joyce O'Shaughnessy, Lee S. Schwartzberg, Stefan Glück, Erhan Berrak, James Song, David Cox, Linda T. Vahdat> ;Breast Cancer Research and Treatment. 2014 Apr 4
55 citations
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling
Frankie A. Holmes, Virginia Espina, Lance A. Liotta, Yasir Nagarwala, Michael A. Danso, Kristi McIntyre, Cynthia Osborne, Thomas Anderson, Lea Krekow, Joanne L. Blum, ...> ;BMC Research Notes. 2013 Dec 5
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer...
Holmes FA, Nagarwala YM, Espina VA, Liotta LA, Danso MA, Gallagher RI, McIntyre K, Osborne CRC, Mahoney JM, Florance AM, Anderson TC, O'Shaughnessy J> ;J. Clin. Oncol.. 2011-05-20
Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Explo...
Pippen JE, Paul D, Stokoe CT, Blum JL, Krekow L, Holmes FA, Lindquist DL, Sedlacek SM, Rivera RR, Brooks RJ, Vukelja SJ, McIntyre K, Lopez-Diaz C, O'Shaughnessy J> ;J. Clin. Oncol.. 2011-05-20
14 citations
Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Nicholas J. Robert, Paul Conkling, Mark Allen O'Rourke, Paul R. Kuefler, Kristi J. McIntyre, Feng Zhan, Lina Asmar, Yanping Wang, Oluwatoyin O. Shonukan, Joyce O'Shaug...> ;Breast Cancer Research and Treatment. 2011 Feb 1
20 citations
Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adju...
David M. Loesch, F. Anthony Greco, Neil Senzer, Howard A. Burris, John D. Hainsworth, Stephen E. Jones, Svetislava J. Vukelja, John Sandbach, Frankie A. Holmes, Scot S...> ;Journal of Clinical Oncology. 2010 Jun 20
13 citations
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
Kristi McIntyre, Patrick V. Acevedo, Carlos A. Encarnacion, Karen L. Tedesco, Yunfei Wang, Lina Asmar, Joyce A. O'Shaughnessy> ;Breast Cancer Research and Treatment. 2009 May 21
396 citations
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research...
Stephen E. Jones, Frankie A. Holmes, Joyce O'Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja, Kristi J. McIntyre, John Pippen, James H. Bordelon, Robert Kirby, John...> ;Journal of Clinical Oncology. 2009 Mar 10
Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer.
Robert NJ, Conkling PR, Kuefler PR, McIntyre KJ, Zhan F, Asmar L, Wang Y, Shonukan OO, O'Shaughnessy J> ;J. Clin. Oncol.. 2008-05-20
23 citations
Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
David M. Loesch, Lina Asmar, Kristi McIntyre, Lisa Doane, Michael A. Monticelli, Devchand Paul, Svetislava J. Vukelja, Mauro Orlando, LaTrice G. Vaughn, Feng Zhan, Kri...> ;Clinical Breast Cancer. 2008 Apr 1
381 citations
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
Stephen E. Jones, Michael Savin, Frankie A. Holmes, Joyce O'Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja, Kristi J. McIntyre, John Pippen, James H. Bordelon, Rob...> ;Journal of Clinical Oncology. 2006 Dec 1
Join now to see all

Press Mentions

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024

Hospital Affiliations

Texas Health Presbyterian Hospital DallasDallas, Texas